Protagonist Therapeutics, Inc. (PTGX) — Fair Value Analysis

Base-case fair value (P50): $101.22 · Current price: $112.86 · Verdict: Fairly Valued

The Verdict on PTGX

Our Monte Carlo simulations indicate that PROTAGONIST THERAPEUTICS INC (PTGX) is Fairly Valued in the current market. Despite a $112.86 that stands against our median fair value (P50) of $101.22, resulting in -10.3%, the broader probabilistic distribution supports this assessment. This verdict suggests that while the stock trades at a premium to its P50 fair value, it remains within a reasonable range considering the various forward scenarios simulated.

How PTGX stacks up against peers

While a specific sector is not provided for PTGX, our analysis highlights a "weak" quality tier for the company, reflecting challenges in its operational and financial health. This "weak" quality tier is a critical input into our Monte Carlo simulations, shaping the range of possible outcomes for PTGX. Even with a $112.86 and a median fair value of $101.22 that places it as Fairly Valued, investors should be mindful of the inherent risks associated with a weaker quality profile. This contextualizes the -10.3%, suggesting that even a slight overvaluation against the median fair value in a "weak" company requires careful consideration.

What this means for investors

For investors tracking PTGX, the "Fairly Valued" verdict, coupled with a "weak" quality tier, suggests a balanced, yet cautious, outlook. The relationship between the $112.86 and our $101.22 fair value, reflected in the -10.3%, indicates that current prices are largely reflective of the company's intrinsic value, as modeled through thousands of forward-looking scenarios. FairCurve’s simulations aim to cut through market noise, providing a probabilistic view. To fully understand the range of outcomes, including the specific bear and bull case scenarios and the overall probability of upside, we invite you to sign up for a free FairCurve account.